Man Group
COGT icon

Man Group’s Cogent Biosciences COGT Stock Holding History

Man Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.5M Sell
194,801
-97,281
-33% -$3.59M 0.01% 954
2025
Q4 		$10.4M Buy
+292,082
New +$8.21M 0.02% 779

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Man Group's COGT Position: Q1 2026 in Review

Man Group reduced its Cogent Biosciences (COGT) stake by 33% in Q1 2026, selling an estimated $3.59M and leaving 194,801 shares worth $7.5M. The position accounts for 0.01% of the portfolio, ranked #954.

Man Group first reported a position in COGT in Q4 2025 and has held it in 2 quarters since. The position peaked at $10.4M in Q4 2025. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Man Group held 194,801 shares of Cogent Biosciences worth $7.5M as of Q1 2026.
  • Man Group sold 97,281 Cogent Biosciences shares in Q1 2026, an estimated $3.59M.
  • Cogent Biosciences made up 0.01% of Man Group's portfolio in Q1 2026, its #954 holding.
  • Man Group first reported a position in Cogent Biosciences in Q4 2025 and has held it in 2 quarters since.
  • Man Group's Cogent Biosciences position peaked at $10.4M in Q4 2025.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Man Group's 13F filing for Q1 2026, filed 15 May 2026.